Hemostasis Products Market Report 2026

Hemostasis Products Market Overview

• Hemostasis Products market size has reached to $1.8 billion in 2025 • Expected to grow to $2.52 billion in 2030 at a compound annual growth rate (CAGR) of 7.2% • Growth Driver: Surging Incidence Of Cardiac Disorders Fuels Expansion Of The Hemostasis Products Market • Market Trend: Emerging Trends in Advanced Topical Hemostasis Solutions • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hemostasis Products Market?

Hemostasis products refer to medical substances or devices used to control bleeding and promote clotting (hemostasis) in various medical settings. These products are crucial for managing bleeding disorders and promoting wound healing, while also ensuring that the body's clotting mechanisms function properly. The main types of hemostasis products are topical hemostasis products, infusible hemostasis products, and advanced hemostasis products. Topical hemostasis products refer to medical substances or materials designed to stop or control bleeding. It includes various applications, such as trauma, surgery, hemophilia, myocardial infarction, and others, and the main end-users are hospitals, clinics and others.

What Is The Hemostasis Products Market Growth Forecast?

The hemostasis products market size is expected to see strong growth in the next few years. It will grow to $2.52 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing adoption of advanced biological and synthetic agents, rising demand for minimally invasive surgical solutions, expansion of trauma care infrastructure, growing focus on faster wound healing outcomes, increasing innovation in clotting technologies. Major trends in the forecast period include increasing adoption of advanced hemostatic agents, rising use of topical and sealant-based products, growing demand for rapid bleeding control solutions, expansion of hemostasis applications in surgery and trauma, enhanced focus on biocompatible materials.

Global Hemostasis Products Market Segmentation

1) By Product: Topical Hemostasis Product, Infusible Hemostasis Product, Advanced Hemostasis Product 2) By Application: Trauma, Surgery, Hemophilia, Myocardial Infarction, Other Applications 3) By End User: Hospitals, Clinics, Other End Users Subsegments: 1) By Topical Hemostasis Product: Hemostatic Agents, Tissue Sealants, Fibrin Sealants 2) By Infusible Hemostasis Product: Platelet-Rich Plasma (PRP), Coagulation Factors, Prothrombin Complex Concentrates 3) By Advanced Hemostasis Product: Biological Adhesives, Synthetic Hemostatic Agents, Hemostatic Dressings

What Is The Driver Of The Hemostasis Products Market?

The rising prevalence of cardiac disorders is expected to propel the growth of the hemostasis products market going forward. Cardiac disorders refer to a broad category of medical conditions and diseases that affect the heart and blood vessels. Hemostasis products are valuable in managing bleeding associated with cardiac disorders, and prevention and treatment of cardiac disorders. Hemostasis products can minimize blood loss, reducing the need for blood transfusions and potential complications in cardiac disorders. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024 up 4.0% from 224.4 per 100,000 in 2023. Therefore, the rising prevalence of cardiac disorders is driving the growth of the hemostasis products industry going forward.

Key Players In The Global Hemostasis Products Market

Major companies operating in the hemostasis products market are Pfizer Inc., Medtronic plc, Johnson And Johnson Pvt. Ltd., Stryker Corporation, Baxter International Inc., F. Hoffmann-La Roche Ltd., BBraun Melsungen AG, Fresenius Kabi AG, Grifols S.A., Terumo BCT Inc., Smith And Nephew plc, Ethicon Suture Laboratories, Cook Medical, Teleflex Incorporated, Integra LifeSciences Corporation, Haemonetics Corporation, Z-Medica LLC, Tricol Biomedical, Hem Con Medical Technologies Inc., Hemostasis LLC, CuraMedical BV, Ethicon Suture Laboratories

Global Hemostasis Products Market Trends and Insights

Major companies operating in the hemostasis products market are focusing on developing next-generation topical hemostatic powders, such as advanced polysaccharide-based powder systems designed for rapid bleeding control in surgical and emergency settings. Topical hemostatic powders refer to passive, absorbable agents that promote clot formation by concentrating blood solids and accelerating the natural coagulation cascade at the bleeding site. For instance, in July 2023, Baxter International Inc., a US-based medical products company, launched its PERCLOT Absorbable Hemostatic Powder in the United States, a ready-to-use, plant-based hemostatic agent intended for mild bleeding during a wide range of surgical procedures. The product features fast wettability, easy laparoscopic applicator compatibility, and broad procedural versatility, enabling surgeons to achieve effective intraoperative bleeding control with improved convenience and efficiency.

What Are Latest Mergers And Acquisitions In The Hemostasis Products Market?

In May 2025, Merit Medical Systems Inc., a US-based medical device company focused on interventional and surgical products, acquired Biolife Delaware LLC for approximately US$120 million. With this acquisition, Merit Medical Systems aims to broaden and strengthen its hemostasis solutions portfolio by adding Biolife’s StatSeal and WoundSeal topical hemostatic product lines, enhance its offerings for post-procedure bleeding control across vascular access and wound care settings, and expand its presence in the hemostasis products market. Biolife Delaware LLC is a US-based manufacturer of topical hemostatic products used for rapid external bleeding control in vascular access and wound care applications.

Regional Outlook

North America was the largest region in the hemostasis products market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Hemostasis Products Market?

The hemostasis products market consists of sales of hemostatic agents, hemostatic powders, hemostatic sponges, collagen, oxidized regenerated cellulose, gelatin, polysaccharide, flowable complex, thrombin complex, fibrin complex, synthetic sealants, and fresh frozen plasma. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.